Andropause Support
This protocol is for men in midlife with symptomatic low-T presentation — fatigue, loss of morning erections, declining libido, mood flatness, reduced muscle mass and strength despite training — who want to explore peptide-based options BEFORE committing to traditional testosterone replacement therapy (TRT). The decision between TRT and peptide-based HPG stimulation is not minor: TRT shuts down endogenous testicular function (a one-way door for many users; restoring fertility after years on TRT is difficult and not guaranteed). Peptide-based HPG stimulation (kisspeptin) preserves the upstream signaling that drives natural testosterone production.
This protocol assumes you have already had baseline labs (total T, free T, SHBG, LH, FSH, estradiol, prolactin, hematocrit, lipid panel, fasting glucose + A1c, PSA + DRE if 40+) and you have had — or are about to have — that decision conversation with an endocrinologist or men's-health clinician. The protocol is NOT a substitute for that consultation.
It is NOT for men with prostate cancer history, severe cardiovascular disease, untreated severe sleep apnea, polycythemia (hematocrit >54%), or active fertility-treatment cycles. It is NOT for men under 30 with low-T presentation — that needs an endocrinology workup for an underlying cause, not peptide adjuncts.
Phases
Phase 1 — Baseline workup + cofactor foundation (B12)
weeks 1-4Get the baseline labs in hand BEFORE peptide adjustments — total T, free T, SHBG, LH, FSH, estradiol, prolactin, hematocrit, lipid panel, fasting glucose + A1c, PSA + DRE if 40+. B12 deficiency is common in midlife and presents with overlapping symptoms (fatigue, mood flatness, cognitive load) — addressing it first prevents misattributing B12-deficiency symptoms to "low T" and adding peptides that won't fix the underlying issue. B12 1000mcg SubQ weekly is the standard repletion dose; methylcobalamin is the bioavailable form.
- B12 (Methylcobalamin)1 mg · once weekly · morning
1000mcg SubQ once weekly. Standard repletion dose for B12 deficiency. If baseline B12 is in the lower normal range (200-400 pg/mL), use this dose for 4-8 weeks before re-checking; many users get partial symptomatic improvement from B12 alone, which clarifies how much of the 'low T' picture is actually B12 deficiency.
What “working” looks like
After 4 weeks of B12: modest energy improvement, modest cognitive clarity, no expectation of muscle/strength/libido changes (B12 doesn't drive those — they need the T-axis work in Phase 2+). The labs come back, the TRT-vs-peptide conversation happens with the clinician. The cleanest read of Phase 1 is that you've separated the B12-deficiency signal from the actual T-axis question; Phase 2 then targets the right problem.
Decision criteria
Phase 1 is mandatory before Phase 2 — do not skip the workup. After 4 weeks: review labs with your clinician. Three possible outcomes: (a) B12 was the issue and symptoms largely resolved — stay on Phase 1 maintenance and re-evaluate in 3 months; (b) labs show frank hypogonadism (total T <300 ng/dL with symptoms, low LH/FSH) and clinician recommends TRT — that decision is outside this protocol's scope; (c) labs show sub-clinical or borderline picture and you + clinician decide to try Phase 2 first.
Labs to pull
- Total testosterone, free testosterone, SHBG (baseline T-axis)
- LH + FSH (upstream HPG-axis function — needed to interpret T values)
- Estradiol (E2 sensitive assay), prolactin
- Hematocrit (T elevation drives erythrocytosis)
- Lipid panel + fasting glucose + A1c (cardiometabolic baseline)
- PSA + DRE if 40+ (prostate baseline before any T-axis work)
- B12 (serum + methylmalonic acid if symptoms suggest deficiency despite normal-range serum value)
- TSH + free T4 (thyroid is the other common 'low T mimic')
Phase 2 — HPG-axis stimulation (+Kisspeptin)
weeks 4-12OPTIONAL — ONLY after labs reviewed with clinician AND you have decided against TRT (or alongside a clinician who specifically supports a peptide-first trial). Kisspeptin 100mcg SubQ once daily — community dosing extrapolated from research protocols. The Imperial College pulsatile-research dosing (~6.4-12.8mcg per pulse every 90 minutes) is not practical for community use; community practice is single daily SubQ administration. Mechanism: kisspeptin is upstream of GnRH → LH → testicular T production, preserving the natural HPG-axis architecture (unlike TRT, which shuts the upstream off). Continue Phase 1 B12 weekly.
- B12 (Methylcobalamin)1 mg · once weekly · morning
Continue Phase 1 cofactor dose.
- Kisspeptin100 mcg · once daily · morning
100mcg SubQ once daily, morning. Community-practice dosing — the research literature uses pulsatile protocols (~6.4-12.8mcg per pulse every 90 minutes) that are not practical outside clinical-research contexts. Community single-daily extrapolation has no clinical-outcome data for the off-label 'natural T booster' use case in eugonadal men; users running this should be honest that they're operating on mechanism + research-context evidence, not on validated clinical outcomes.
What “working” looks like
At 8-12 weeks: re-check labs (total T, free T, LH, FSH, estradiol, hematocrit, PSA). The expected pattern in a responder: LH and FSH rise (mechanism working — upstream HPG axis stimulated); total T modestly rises; estradiol may also rise (aromatization downstream); subjective improvements in morning erections, libido, energy, mood. The expected pattern in a non-responder: labs don't move, symptoms don't shift. Honest framing: kisspeptin works upstream of the pituitary; if your pituitary itself is the bottleneck (secondary hypogonadism), upstream stimulation can help. If your testicular function is the bottleneck (primary hypogonadism), kisspeptin will not — you need TRT or hCG-style direct testicular stimulation, which is outside this protocol.
Decision criteria
At week 12, re-review labs with clinician. If LH/FSH rose and T improved and symptoms improved: this is your working protocol — continue. If LH/FSH rose but T didn't follow: testicular bottleneck — kisspeptin isn't the right tool; revisit the TRT conversation. If neither LH/FSH nor T moved: pituitary itself isn't responding to kisspeptin — this protocol isn't working for your physiology; discontinue and revisit clinical care. If T rose, symptoms didn't: the T elevation isn't doing the work you hoped — either symptoms have another driver (sleep, depression, cardiovascular, B12 still under-replete) or your sensitivity to T is the limiting factor.
Labs to pull
- Total + free T, SHBG (re-check)
- LH + FSH (the upstream effect that confirms kisspeptin is working at all)
- Estradiol (aromatization downstream of T rise)
- Hematocrit (T elevation drives erythrocytosis; flag if >52% trending toward 54%)
- PSA (prostate monitoring on any T-axis work)
Phase 3 — GH-axis layer for body comp + recovery (+CJC/Ipa)
weeks 12+, layered on Phase 1+2OPTIONAL. Add CJC-1295 / Ipamorelin 250mcg/250mcg SubQ 5 days/week before bed (fasted 2+ hours) for users whose body-composition + recovery goals weren't addressed by Phase 2 alone. The blend is the most-used GH-axis stack in the community; mechanism is well-characterized (CJC = GHRH analog amplifies GH pulse; Ipa = ghrelin-receptor agonist triggers GH release). Combination-specific RCT for body comp is absent — evidence is the individual components' PK/PD work plus community experience. Continue Phase 1 B12 + Phase 2 Kisspeptin throughout.
- B12 (Methylcobalamin)1 mg · once weekly · morning
Continue Phase 1 cofactor dose.
- Kisspeptin100 mcg · once daily · morning
Continue Phase 2 HPG-axis stimulation.
- CJC-1295 / Ipamorelin250 mcg · 5 days per week · before bed, fasted 2+ hours
10 units SubQ (250mcg CJC + 250mcg Ipa) 5 days/week, before bed, fasted 2+ hours. Insulin from a recent meal blunts the ghrelin-pathway response, so dose fasted. Standard community blend pattern.
What “working” looks like
At 8-12 weeks of Phase 3: IGF-1 rises (the on-target downstream marker — pull this at week 8); body composition shifts (modest lean-mass gain, modest visceral fat loss) typically lag the IGF-1 rise by 2-3 months; sleep quality often improves before composition does (GH peaks in slow-wave sleep). Recovery from training improves modestly.
Decision criteria
At week 12-16 of Phase 3: re-check IGF-1, glucose, A1c. If IGF-1 rose appropriately + body composition shifted in the expected direction: continue with annual lab review. If IGF-1 didn't move: blend isn't working as expected — re-check reconstitution + injection technique + dose timing (insulin blunting from meal proximity is the most common issue). Cycle off every 8-12 weeks for 4-8 weeks; long-term continuous GH-secretagogue use is not well-characterized for safety.
Labs to pull
- IGF-1 (on-target marker for GH-axis stimulation)
- Fasting glucose + A1c (GH is counter-regulatory to insulin)
- All Phase 2 markers (continue trending T-axis + prostate)
Cautions
- Prostate cancer history is a HARD EXCLUSION for the entire protocol. T elevation drives prostate growth; any history of prostate cancer means T-axis stimulation is contraindicated unless your oncology team specifically approves it (rare in practice). Active prostate cancer or PSA elevation that hasn't been worked up means a urology consultation BEFORE starting, not after.
- Severe cardiovascular disease — recent MI, unstable angina, severe heart failure — is a contraindication. T elevation has complex cardiovascular interactions; the safety data in users with active CV disease is limited and the risk-benefit calculation belongs with a cardiologist, not a community protocol.
- Untreated severe sleep apnea is a contraindication. T elevation can worsen apnea; the standard sequence is sleep study + CPAP titration FIRST, then re-evaluate T-axis goals once apnea is controlled. Adding T-axis stimulation to undiagnosed apnea is a common community failure mode.
- Polycythemia / elevated hematocrit (>52% trending toward 54%) is a contraindication or hold. T elevation drives erythrocytosis; users with high baseline hematocrit are at risk of significant clinically-relevant elevation. Monitor at baseline + every 8-12 weeks during active Phase 2+3. Therapeutic phlebotomy may be needed if hematocrit climbs.
- Fertility decision matters NOW. TRT shuts down testicular function (often permanently or near-permanently). Kisspeptin preserves it. If you and your partner want to conceive within the next 12-24 months, the peptide path is the fertility-preserving option — TRT is the option that closes that door. This is the conversation to have with both the men's-health clinician and your partner BEFORE starting any T-axis work.
- GH-axis stimulation (Phase 3) carries WADA-banned status for competitive athletes — recreational use is one thing, federation-level testing is another. If you're competing in any federation that drug-tests, Phase 3 is off-table.
- Active malignancy of any kind is a hard exclusion for Phase 3 (CJC/Ipa). The IGF-1 elevation is the theoretical concern in any tissue with cancerous cells. Phase 2 (kisspeptin) has its own sex-steroid-axis concerns for hormone-sensitive malignancies.
- Pediatric + young-adult exclusion. This protocol is for men 30+ with confirmed midlife low-T pattern. Low T in younger men (<30) warrants endocrinology workup for underlying cause (pituitary, gonadal, systemic), not community peptide adjuncts.
Discuss with your clinician
- Before starting anything: get the baseline labs (Phase 1 lab list above) and have the TRT-vs-peptide decision conversation with an endocrinologist or men's-health clinician. This conversation determines the entire path. Bring this protocol document to the appointment.
- Prostate baseline: PSA + DRE if you are 40+ before starting any T-axis work. If you have any prostate symptoms (urinary urgency, weak stream, nocturia) or family history of prostate cancer, urology consultation BEFORE peptide use, not after.
- Sleep apnea screen if you have ANY symptoms (snoring + daytime fatigue + witnessed apneas; partner observations; falling asleep at the wheel risk). Treat the apnea first; revisit T-axis after CPAP titration.
- Cardiovascular risk assessment if you have hypertension, lipid concerns, family history of early CV disease, or any cardiac symptoms. A cardiologist consult before adding T-axis stimulation is reasonable for users with risk factors.
- Fertility planning: if you want to conceive within 12-24 months, make that explicit in the clinician conversation — it changes the recommendation toward kisspeptin (preserves) and away from TRT (shuts down). Bring your partner into the discussion.
- Quarterly during active Phase 2+3: lab panel (T, free T, LH, FSH, estradiol, hematocrit, PSA if 40+, IGF-1 if Phase 3 active). Trend monitoring matters more than single values. Bring results to the clinician follow-up.
Evidence summary
Tier 3 protocol overall — anchored by the off-label use of kisspeptin in eugonadal men (the population most likely to use this protocol), which is Tier 3 per the skill's Rule 6 (Tier 2 hypogonadism evidence does NOT propagate to eugonadal use). Phase 1 B12 is Tier 2 for confirmed deficiency. Phase 2 kisspeptin: Tier 2 for hypothalamic amenorrhea and IVF triggering (validated clinical research from Imperial College / Dhillo lab); Tier 2 for hypogonadotropic hypogonadism (Jayasena 2014 follow-ups); Tier 3 for the off-label "natural T booster" use case this protocol targets. Phase 3 CJC/Ipa: Tier 2 for GH/IGF-1 axis restoration (component PK/PD); Tier 3 for body-composition outcomes (no combination RCT). Honest framing: the strongest evidence in this protocol is for indications most users in the andropause cohort are NOT — they're using kisspeptin off-label and CJC/Ipa without combination outcome data. The clinician conversation is load-bearing, and the protocol surface should not appear to substitute for it.
Components (3)
- B12 (Methylcobalamin)Vitamin (methylcobalamin)
- KisspeptinKISS1R agonist (hypothalamic neuropeptide)
- CJC-1295 / IpamorelinBlend
Often combined with
- Body Composition
CJC/Ipa is in both protocols (Body Composition Phase 2 + Andropause Phase 3). If running both, do NOT double-dose — single 250/250mcg blend 5x/week covers both surfaces. Users running both typically have midlife low-T + body-composition goals; the Andropause Phase 2 kisspeptin layer addresses the upstream T-axis question that Body Composition alone does not.
- Longevity
MTOR-vs-IGF1 tension. Longevity Phase 2 (NR / rapamycin) inhibits or modulates mTOR for longevity goals; Andropause Phase 3 (CJC/Ipa) raises IGF-1, which activates mTOR pathways. Running both simultaneously is mechanistically incoherent — you're stimulating IGF-1 and inhibiting mTOR at the same time. The honest answer is to choose one priority at a time, not run both Phase 3 layers concurrently. Phase 2 kisspeptin + Phase 2 longevity (NR substrate) is fine.
Ready to add this protocol to your stack?
Phase 1 entries start today; later phases are future-dated and ready to edit.